TLDR
- Artelo Biosciences (ARTL) stock surged approximately 600% on Friday, March 27, 2026.
- The company announced an $11M private placement priced at-the-market under Nasdaq rules.
- 3,188,407 common stock units were offered at $3.45 per share combined with warrants.
- Warrants cover up to 6,376,814 additional shares at an exercise price of $3.20, potentially adding $20.4M.
- Net proceeds will go toward working capital, general corporate purposes, and repaying bridge debt.
Artelo Biosciences (ARTL) was trading around $3.45 per share on Friday — the same price as its private placement offering — after the stock rocketed roughly 600% on the day.
Artelo Biosciences, Inc., ARTL
The clinical-stage pharmaceutical company announced it has entered into definitive agreements to sell 3,188,407 shares of common stock, or pre-funded warrants in lieu thereof, in a private placement priced at-the-market under Nasdaq rules.
The combined purchase price is $3.45 per share, inclusive of accompanying warrants.
The deal is expected to close on or about March 30, 2026, subject to standard closing conditions.
Gross proceeds from the offering are expected to reach approximately $11 million, before placement agent fees and other expenses are deducted.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction.
Warrants Add Potential Upside
Alongside the stock offering, investors will receive warrants to purchase up to 6,376,814 additional shares. That’s roughly double the number of shares being sold outright.
The warrants carry an exercise price of $3.20 per share, are exercisable immediately upon issuance, and expire five and a half years from the registration effectiveness date.
If all warrants are exercised on a cash basis, Artelo could pull in an additional $20.4 million — though the company makes clear there’s no guarantee any warrants will be exercised.
The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered. The company has agreed to file a resale registration statement covering the securities.
How the Money Will Be Used
Artelo said it intends to use net proceeds for working capital, general corporate purposes, and to repay certain bridge debt.
The bridge debt repayment stands out — it signals the company had short-term obligations pressing on its balance sheet heading into this raise.
At its core, this is a capital raise for a small-cap clinical-stage biotech that needed cash. That’s not unusual in this space.
ARTL operates across a pipeline targeting anorexia, cancer, anxiety, dermatologic conditions, pain, inflammation, and eye diseases — all areas tied to lipid-signaling pathway modulation.
The 600% price move is extreme by any measure and likely reflects thin float dynamics alongside renewed attention from retail and speculative traders following the announcement.
As of the announcement date, the private placement remained subject to closing conditions, with the expected close set for March 30, 2026.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
